T cell engagers convert acute tumor killing into endogenous vaccination
T cell engagers (TCEs) redirect T cells to kill tumors by cross-linking CD3ε to a tumor antigen, independently of T cell receptor specificity. Some patients achieve remissions that persist long after drug clearance, but whether TCEs can couple acute cytotoxicity to the generation of lasting adaptive immunity remains un...